Open Access Full Text Article

## CORRIGENDUM **Clinical Applications of Aneuploidies in Evolution of NSCLC Patients:**

Yan X, Liu SM, Liu C. Onco Targets Ther. 2022;15:1355-1368

**Current Status and Application Prospect [Corrigendum]** 

The authors have advised that Xing Yan and Shan Mei Liu should be considered as equally contributed authors for this paper titled "Clinical Applications of Aneuploidies in Evolution of NSCLC Patients: Current Status and Application Prospect" published in OncoTargets and Therapy on November 10, 2022.

The updated author list should read as follows:

Xing Yan<sup>1,\*</sup> Shan Mei Liu<sup>2,\*</sup>, Changhong Liu<sup>1</sup>

<sup>1</sup>The Second Affiliated Hospital of Dalian Medical University, Dalian, 116000, People's Republic of China; <sup>2</sup>Inner Mongolia Medical University, Hohhot, 150110, People's Republic of China

Correspondence: Changhong Liu, The Second Affiliated Hospital of Dalian Medical University, Dalian, 116000, People's Republic of China, Tel +86 17709870870, Email 17709870870@163.com

\*These authors contributed equally to this work

The authors apologize for this oversight.

## **OncoTargets and Therapy**

**Dove**press

141

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy is an international, peer viewed, open access journal reducing of the patiological basis of an earliers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S408586

Received: 14 February 2023 Accepted: 14 February 2023 Published: 1 March 2023

## OncoTargets and Therapy 2023:16 141

cc 0 S © 2023 Yan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.do /epress.com/terms.php you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).